ClinicalTrials.gg
TerminatedNCT02117479Updated Mar 26, 2019Results posted

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

A Phase 3 interventional study of Ruxolitinib and Placebo in Pancreatic Cancer, sponsored by Incyte Corporation. Terminated at 230 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early based on the results of the planned interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Pancreatic Neoplasms by Incyte Corporation — 1 open to participants now, 2 under way, 1 of them phase 3. Pancreatic Neoplasms · Incyte Corporation.

Enrollment
2nd of 10
321 · median 111
Started
2014
with 1 other
Phase 3
3 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 3, and was the 5th registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 10 studies in Pancreatic Neoplasms by Incyte Corporation is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pancreatic Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.

Read the detailed description

This was a randomized, double-blinded, placebo-controlled, Phase 3 study, in which approximately 310 participants with advanced or metastatic adenocarcinoma of the pancreas who have failed, or were intolerant to first-line chemotherapy, were to be randomized (1:1) to one of the following treatment groups:

  • Treatment A (N = 155): Capecitabine + ruxolitinib
  • Treatment B (N = 155): Capecitabine + placebo

Treatment consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and ruxolitinib/placebo was self-administered daily for each cycle. Treatment for all participants continued as long as the regimen was tolerated, and the participant did not meet discontinuation criteria. Participants who discontinued study treatment before study termination were monitored for safety up to 30-35 days from the end of treatment. All participants were followed for survival until study termination or the safety follow-up visit.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Metastatic pancreatic cancer
  • Metastatic pancreatic adenocarcinoma that is recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the pancreas.
  • Advanced adenocarcinoma of the pancreas that is inoperable or .
  • (ECOG) performance status 0 to 2
  • Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including and/or adjuvant therapy).
  • ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.
  • Radiographically measurable or evaluable disease
  • Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

    1. mGPS of 1: C-reactive protein >10 mg/L and albumin ≥35 g/L
    2. mGPS of 2: C-reactive protein >10 mg/L and albumin \<35 g/L

Exclusion criteria

Exclusion Criteria:

  • Received more than 1 prior regimen for advanced or disease.
  • Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment.
  • Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, therapy, or tumor embolization).
  • Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known to active substances, including fluorouracil (5-FU), or ruxolitinib, or any of their .
  • Prior treatment with a JAK inhibitor for any indication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Ruxolitinib plus capecitabine

    Drug: Ruxolitinib · Drug: Capecitabine

  • Active comparator
    Placebo plus capecitabine

    Drug: Placebo · Drug: Capecitabine

Interventions

  • 5 mg tablets to be administered by mouth twice daily (BID)

    Also known as: Jakafi ®, Jakavi ®

  • DrugPlacebo

    5 mg tablets to be administered by mouth twice daily (BID)

  • 150 and 500 mg tablets to be administered by mouth twice daily (BID)

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is reported here based on the number of deaths from randomization up to 6-months or to the data cutoff 11FEB2016.

    Time frame: Randomization until death due to any cause; up to the data cutoff 11FEB2016.

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

    Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.

  2. Percentage of Participants Achieving Progression Free Survival (PFS)

    PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

    Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.

  3. Objective Response Rate (ORR)

    Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

    Time frame: Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.

  4. Duration of Response

    Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) until the first date Progressive Disease (PD) was objectively documented or until the date of death.

    Time frame: Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.

  5. Participants With Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug (ruxolitinib or placebo). A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

    Time frame: Baseline through approximately 30 days post treatment discontinuation; up to 6-months or to the data cutoff 11FEB2016.

07

Results

Posted Jul 11, 2017
Limitations and caveats
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation at the recommendation of the Data Monitoring Committee.

Participant flow

Participants with advanced or metastatic adenocarcinoma of the pancreas who had failed or were intolerant to first-line chemotherapy were randomized in the study.

Participant flow — Overall Study
MilestoneRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Started161160
Completed54
Not completed156156
Withdrew: Death138
Withdrew: Adverse event816
Withdrew: Subject decision89
Withdrew: Disease progression104108
Withdrew: Noncompliance with study treatment10
Withdrew: Study terminated by the sponsor46
Withdrew: Physician decision72
Withdrew: Other unspecified117

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is reported here based on the number of deaths from randomization up to 6-months or to the data cutoff 11FEB2016.

Time frame:
Randomization until death due to any cause; up to the data cutoff 11FEB2016.
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Observed113124
Censored4836
Statistical analysis
  • Ruxolitinib Plus Capecitabine vs Placebo Plus Capecitabine · Hazard ratio (hr): 0.969 · 95% CI 0.747 to 1.256
SecondaryProgression-free Survival (PFS)

Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

Time frame:
Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Reported as:
Median · days
Progression-free Survival (PFS)
daysRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Progression-free Survival (PFS)43.0 (41.0 to 46.0)44.0 (42.0 to 48.0)
Statistical analysis
  • Ruxolitinib Plus Capecitabine vs Placebo Plus Capecitabine · Hazard ratio (hr): 1.056 · 95% CI 0.827 to 1.348
SecondaryPercentage of Participants Achieving Progression Free Survival (PFS)

PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

Time frame:
Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Reported as:
Median · percentage of participants
Percentage of Participants Achieving Progression Free Survival (PFS)
percentage of participantsRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Survival rate at 3 months18.9 (12.7 to 25.9)19.8 (13.6 to 26.8)
Survival rate at 6 months6.1 (2.5 to 12.2)5.7 (2.3 to 11.3)
Survival rate at 9 months2.5 (0.5 to 7.5)3.4 (1.0 to 8.5)
Survival rate at 12 months2.5 (0.5 to 7.5)NA (NA to NA)
SecondaryObjective Response Rate (ORR)

Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

Time frame:
Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Objective response3.71.9
Complete response00
Partial response3.71.9
SecondaryDuration of Response

Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) until the first date Progressive Disease (PD) was objectively documented or until the date of death.

Time frame:
Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Reported as:
Median · days
Duration of Response
daysRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Duration of ResponseNA (NA to NA)NA (NA to NA)
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs)

A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug (ruxolitinib or placebo). A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

Time frame:
Baseline through approximately 30 days post treatment discontinuation; up to 6-months or to the data cutoff 11FEB2016.
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Participants who had any TEAEs152152
Participants who had treatment-related TEAEs7359
Participants who had SAEs9483
Participants who had Grade 3 or higher TEAEs112113
Participants hospitalized because of a TEAE8975
Participants discontinued treatment due to TEAE1222
Participants with a dose modification due to TEAE6848
Participants on concomitant medication due to TEAE131122
Participants with procedure performed due to TEAE6046
Participants who had a fatal TEAE2015

Adverse events

Collected over From the first dose of study medication through study termination up to 6-months or to the data cutoff 11Feb2016.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib Plus Capecitabine—94/153 (61.4%)147/153 (96.1%)
Placebo Plus Capecitabine—83/154 (53.9%)145/154 (94.2%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
Abdominal painGastrointestinal disorders6/15319/154
PyrexiaGeneral disorders8/1531/154
VomitingGastrointestinal disorders7/1534/154
DehydrationMetabolism and nutrition disorders7/1534/154
PneumoniaInfections and infestations4/1537/154
AscitesGastrointestinal disorders5/1531/154
DiarrhoeaGastrointestinal disorders5/1534/154
SepsisInfections and infestations5/1535/154
HyponatraemiaMetabolism and nutrition disorders5/1531/154
Renal failure acuteRenal and urinary disorders5/1531/154
Most frequent other events
Showing 10 of 42
Most frequent other events
EventRuxolitinib Plus CapecitabinePlacebo Plus Capecitabine
FatigueGeneral disorders47/15350/154
NauseaGastrointestinal disorders45/15349/154
Abdominal painGastrointestinal disorders36/15349/154
Decreased appetiteMetabolism and nutrition disorders30/15347/154
VomitingGastrointestinal disorders30/15346/154
AnemiaBlood and lymphatic system disorders45/15322/154
DiarrheaGastrointestinal disorders42/15336/154
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders37/15326/154
Oedema peripheralGeneral disorders18/15335/154
ConstipationGastrointestinal disorders33/15327/154

Baseline characteristics

The intent-to-treat (ITT) population consisted of all participants randomized to the study.

Age, Continuous
Age, Continuous(years)Ruxolitinib Plus CapecitabinePlacebo Plus CapecitabineTotal
Mean67.3 ± 9.3565.6 ± 9.5566.4 ± 9.48
Age, Customized
Age, Customized(participants)Ruxolitinib Plus CapecitabinePlacebo Plus CapecitabineTotal
≤ 65 years6568133
> 65 years9692188
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib Plus CapecitabinePlacebo Plus CapecitabineTotal
Female6664130
Male9596191
08

Study locations

230 sites
  • Avondale, Arizona, United States
  • Chandler, Arizona, United States
  • Gilbert, Arizona, United States
  • Glendale, Arizona, United States
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Surprise, Arizona, United States
  • Tucson, Arizona, United States
  • Hot Springs, Arkansas, United States
  • Jonesboro, Arkansas, United States
  • Anaheim, California, United States
  • Bakersfield, California, United States
  • Berkeley, California, United States
  • Beverly Hills, California, United States
  • Chula Vista, California, United States
  • Covina, California, United States
  • Downey, California, United States
  • El Cajon, California, United States
  • Fullerton, California, United States
  • Gilroy, California, United States
  • Glendale, California, United States
  • La Mesa, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Lynwood, California, United States
  • Modesto, California, United States
  • Montebello, California, United States
  • Northridge, California, United States
  • Oceanside, California, United States
  • Orange, California, United States
  • Redondo Beach, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • San Luis Obispo, California, United States
  • Santa Ana, California, United States
  • Santa Maria, California, United States
  • Santa Monica, California, United States
  • Torrance, California, United States
  • Whittier, California, United States
  • Aurora, Colorado, United States
  • Boulder, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Grand Junction, Colorado, United States
  • Longmont, Colorado, United States
  • Thornton, Colorado, United States
  • New Britain, Connecticut, United States
  • New Haven, Connecticut, United States
  • Southington, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Newark, Delaware, United States
  • Boca Raton, Florida, United States
  • Hollywood, Florida, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • Atlanta, Georgia, United States
  • Austell, Georgia, United States
  • Carrollton, Georgia, United States
  • Cartersville, Georgia, United States
  • Douglasville, Georgia, United States
  • Marietta, Georgia, United States
  • Newnan, Georgia, United States
  • Rome, Georgia, United States
  • Thomasville, Georgia, United States
  • Arlington Heights, Illinois, United States
  • Chicago, Illinois, United States
  • Hinsdale, Illinois, United States
  • Niles, Illinois, United States
  • Urbana, Illinois, United States
  • Goshen, Indiana, United States
  • Indianapolis, Indiana, United States
  • Topeka, Kansas, United States
  • Ashland, Kentucky, United States
  • Louisville, Kentucky, United States
  • Metairie, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Scarborough, Maine, United States
  • Annapolis, Maryland, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Rockville, Maryland, United States
  • Worcester, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Lansing, Michigan, United States
  • Woodbury, Minnesota, United States
  • Bolivar, Missouri, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Kalispell, Montana, United States
  • Hastings, Nebraska, United States
  • Omaha, Nebraska, United States
  • Papillion, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Lebanon, New Hampshire, United States
  • East Orange, New Jersey, United States
  • Farmington, New Mexico, United States
  • Binghamton, New York, United States

Showing the first 100 of 230 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018 Aug;36(4):683-695. doi: 10.1007/s10637-018-0580-2. Epub 2018 Mar 6. PubMed 29508247 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Feb 2016, 23 months.

Results were first posted in Jul 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2014
First posted
Apr 21, 2014
StartActual
Mar 2014
Primary completionActual
Feb 2016
CompletionActual
Dec 2016
Results first posted
Jul 11, 2017
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02117479
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
Mar 2014
Primary completion
Feb 2016
Completion
Dec 2016
Results posted
Jul 11, 2017
Last update
Mar 26, 2019

Study contacts

Fitzroy Dawkins, M.D.
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion